Navigation Links
Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial,Results at EuroPCR 2007

BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- Principal investigators for the COSTAR II (CObalt Chromium STent with Antiproliferative for Restenosis) trial, the pivotal study for the CoStar(R) cobalt chromium paclitaxel-eluting coronary stent, presented today the clinical trial results of the study at EuroPCR 2007. The investigators confirmed that the study failed to meet its primary endpoint. Conor previously announced this conclusion in a press release on Monday, May 7, 2007.

The COSTAR II trial compared the CoStar(R) stent with the Taxus Express(2) paclitaxel drug-eluting stent, and was designed to demonstrate non-inferiority at eight-month follow-up with respect to major adverse cardiac events (MACE) in patients with multi-vessel or single-vessel disease. In this trial, MACE was defined as a composite of clinically driven target vessel revascularization (re-treatment), new myocardial infarction (heart attack or MI) related to the target vessel and cardiac death related to an intervened vessel.

At eight-month follow-up, the CoStar(R) stent had significantly higher MACE rate than the Taxus stent (11.0 percent vs. 6.9 percent; p=0.005). This difference was largely due to a significantly higher incidence of clinically driven target vessel revascularization (8.1 percent vs. 4.3 percent; p=0.002). No significant differences were found in terms of cardiac death (0.5 percent for the CoStar(R) stent vs. 0.7 percent for the Taxus stent; p=0.541) or new MI (3.4 percent vs. 2.4 percent; p=0.242).

The investigators also reported that the protocol-defined stent thrombosis rates at nine-month were similar between both arms of the study. The total stent thrombosis rate for the CoStar(R) stent was 0.6 percent vs. 0.1 percent for the Taxus stent (p=0.252).

"Comparably higher re-intervention rates are largely responsible for the outcome of this trial," said Mitchell W. Krucoff, M.D., from Duke Cli
'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:7/28/2014)... July 28, 2014 Reportlinker.com announces that ... its catalogue: Portugal Pharmaceuticals and ... http://www.reportlinker.com/p0207141/Portugal-Pharmaceuticals-and-Healthcare-Report-Q3-2014.html Includes 3 ... Faster-than-expected economic growth last quarter has led us ... upwards. As forecast previously, BMI expects ...
(Date:7/28/2014)... , July 28, 2014  UBM Medica US ... leading online community for medical imaging professionals, explored the ... value-based payment models . The shift from ... how the radiologist,s reimbursement is determined in the ... insight from leaders in the field, who recognized the ...
(Date:7/28/2014)... 2014  MedSpring Urgent Care, an Austin -based ... Lamar Blvd., Austin, TX 78704 on Saturday, ... the southeast corner of Barton Springs Rd. and S. ... 9 p.m. daily, including weekends and holidays. With existing ... Austin , Anderson Mill , Cedar Park ...
Breaking Medicine Technology:Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Diagnostic Imaging Delves into Measuring the Radiologist's Value 2MedSpring Urgent Care opens Barton Springs walk-in clinic in Austin, TX 2
... May 17 Xenon Pharmaceuticals Inc. is pleased to announce ... Vice President, Research and Development. , ... "We are delighted to welcome Tarek to the Xenon team," ... world-class R&D executive whose experience in discovering products, a number of which ...
... TAI,AN, China , May ... CBPO ) ("China Biologic" or the "Company"), ... the People,s Republic of,China ("PRC"), operating through ... Ltd. ("Taibang") and Guiyang Dalin,Biologic Technologies Co., Ltd. ...
Cached Medicine Technology:Xenon Announces Appointment of EVP, Research & Development 2China Biologic Products Announces First Quarter 2010 Results 2China Biologic Products Announces First Quarter 2010 Results 3China Biologic Products Announces First Quarter 2010 Results 4China Biologic Products Announces First Quarter 2010 Results 5China Biologic Products Announces First Quarter 2010 Results 6China Biologic Products Announces First Quarter 2010 Results 7China Biologic Products Announces First Quarter 2010 Results 8China Biologic Products Announces First Quarter 2010 Results 9China Biologic Products Announces First Quarter 2010 Results 10China Biologic Products Announces First Quarter 2010 Results 11China Biologic Products Announces First Quarter 2010 Results 12China Biologic Products Announces First Quarter 2010 Results 13China Biologic Products Announces First Quarter 2010 Results 14China Biologic Products Announces First Quarter 2010 Results 15China Biologic Products Announces First Quarter 2010 Results 16China Biologic Products Announces First Quarter 2010 Results 17China Biologic Products Announces First Quarter 2010 Results 18
(Date:7/29/2014)... July 29, 2014 Tucson-based company ... employer’s benefits package, or health and wellness program, called ... while providing an effective way for employees to use ... of the program, employees specify the amount of each ... , An employer benefits from offering a 401(play)™ plan ...
(Date:7/29/2014)... Guests at Napa Valley's quintessential luxury resort, ... new sleep experience. The top of each luxurious resort bed ... , These expertly crafted, 100% Egyptian cotton white duvets and ... yet upon closer look, words are woven in the linens ... breathe. , Intentional breathing and visualization are keys ...
(Date:7/29/2014)... 2014 In his latest blog post at ... CEO Per Wickstrom has listed 6 ways to light the ... creativity and avoid complacency, but for some it’s a losing ... progressive and powerful ways to help employees get to the ... as a whole.” , According to Per Wickstrom, 6 ways ...
(Date:7/29/2014)... Battle Creek, MI (PRWEB) July 29, 2014 ... treatment program that gets clients off to a great start ... believe in, was a proud sponsor of the National Cherry ... City, MI. , The concert, which was co-sponsored by Miller ... Collective Soul take to the Pepsi Bay Side Music Stage ...
(Date:7/29/2014)... 29, 2014 Launched in 2012 by ... surpassed 20,000 hangovers earlier this year at its Vegas ... expansion and the publication of research data related to ... practice. , The only licensed medical practice dedicated to ... launched in 2012 and treated thousands of patients within ...
Breaking Medicine News(10 mins):Health News:Outski launches 401(play)™ Plan to Employers as Part of an Employee Benefit / Health and Wellness Program 2Health News:Auberge Du Soleil Offers INTENTIONS™ by Peacock Alley on Guests' Beds Providing a Unique Sleep Experience 2Health News:Per Wickstrom’s Latest Blog Post Lists 6 Ways to Light the “Fire” in Employees 2Health News:A Forever Recovery Sponsors National Cherry Festival Kickoff Concert Featuring Collective Soul on July 5 in Traverse City, MI 2Health News:Hangover Heaven Surpasses 20,000 Hangovers 2Health News:Hangover Heaven Surpasses 20,000 Hangovers 3
... Meeting of the American Political Science Association (APSA) will ... Metro Toronto Convention Centre, the InterContinental Toronto Centre, and ... time in its history that the meeting has been ... is the world,s largest gathering of political scientists; almost ...
... , ... its outreach to its current and future patients by its recent launch of accounts ... ... 2009 -- KoolDocs.com, the web,s leading resource for online medical consultations, diagnoses, prescriptions, and ...
... SCHAUMBURG, Ill., Aug. 27 Sagent Pharmaceuticals, Inc., ... has launched fluconazole injection in premix bags. IMS Health estimates ... Sagent will begin marketing and shipping fluconazole bags immediately. , ... again exemplified in our new fluconazole offering, the most recent ...
... , DES PLAINES, Ill. and NEW YORK, ... an agreement with Pfizer Inc to develop a molecular diagnostic test ... presence of gene rearrangements. Pfizer has developed a novel investigational ... many cancers. To be eligible to receive Pfizer,s oral therapy, ...
... , PRINCETON, N.J., Aug. 27 ... rare form of hemophilia are coming together at educational summits ... the Center for Biomedical Continuing Education (CBCE). For the fifth ... families with expert healthcare professionals and fellow patients to address ...
... , , , ... ) today announced that it has launched its newly updated online ... and motivated to live a healthier lifestyle. The free and open-to-everyone ... and other resources that allow people to share their experiences and ...
Cached Medicine News:Health News:105th APSA Meeting, world's largest for the study of politics, will be in Toronto Sept. 3-6 2Health News:KoolDocs.com Increases Online Presence through Social Networking Premium Online Medical Consultation Service Now on Facebook, Twitter, and LinkedIn 2Health News:Sagent Pharmaceuticals Announces Launch of Fluconazole Injection in Premix Ready-to-Use IV Bags 2Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 2Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 3Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 4Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 2Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 3Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 4Health News:Weight Watchers(R) Launches New Community on WeightWatchers.com 2Health News:Weight Watchers(R) Launches New Community on WeightWatchers.com 3
Disposable Lacrimal Dilators...
Fine & Medium Tapers....
Skin Tone External Eyelid Weights...
Contour Design Eyelid Implants....
Medicine Products: